Cargando…
Breakthrough Covid‐19 infections in vaccinated recipients of allogeneic stem cell transplantation
Autores principales: | Fourati, Slim, Robin, Christine, Rodriguez, Christophe, Leclerc, Mathieu, Beckerich, Florence, Pawlotsky, Jean‐Michel, Redjoul, Rabah, Maury, Sébastien |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9349499/ https://www.ncbi.nlm.nih.gov/pubmed/35941883 http://dx.doi.org/10.1002/jha2.512 |
Ejemplares similares
-
Antibody response after second BNT162b2 dose in allogeneic HSCT recipients
por: Redjoul, Rabah, et al.
Publicado: (2021) -
Determinants of SARS-CoV-2 waning immunity in allogeneic hematopoietic stem cell transplant recipients
por: Leclerc, Mathieu, et al.
Publicado: (2022) -
Third Early “Booster” Dose Strategy in France of bnt162b2 SARS-CoV-2 Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients Enhances Neutralizing Antibody Responses
por: Ahmed-Belkacem, Abdelhakim, et al.
Publicado: (2022) -
Antibody response after third BNT162b2 dose in recipients of allogeneic HSCT
por: Redjoul, Rabah, et al.
Publicado: (2021) -
Impact of donor vaccination on recipient response to early SARS-CoV-2 mRNA vaccination after allogeneic HSCT
por: Leclerc, Mathieu, et al.
Publicado: (2022)